CTLA 4 News and Research

RSS

Combination immunotherapy improves treatment response for head and neck cancer

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than patients who received just one immunotherapy drug.

13 Mar 2025

Radiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial.

18 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025

Study finds anti-correlation of KLRG1 and PD-1 expression in tumor fighting T cells

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells."

21 Jan 2025

Research sheds light on how hypoxia affects T cell function in cancer

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective.

14 Dec 2024

Australian research unlocks new path for cancer immunotherapy

Australian-led research is unlocking new ways for immunotherapy to better target cancer.

14 Dec 2024

Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.

9 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

Distinct waves of T cells generated by each dose of combination immunotherapy

A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

29 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

New research uncovers mechanisms behind heart damage from CTLA-4 blockade

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells.

7 Aug 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024